Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025

H1 financial resultats

Published 16 September 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

ESMO 2025

Published 27 July 2025
Categorized as 2025, BT-001, Invir.IO, Press release

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director

Nomination E Quiles

Published 9 July 2025
Categorized as 2025, Press release

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

TG4050

Published 19 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

investor meetings

Published 13 June 2025
Categorized as 2025, Press release

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

ASCO 2025 TG4050 webinar

Published 3 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050

ASCO TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO 2025 TG4050

Published 1 June 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

ASCO Abstract

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

ASCO 2025 TG4050

Published 22 May 2025
Categorized as 2025, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 4 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu